The United Kingdom's first NHS Endobarrier service for advanced diabesity: 1-year outcomes for all 62 treated patients

Robert EJ Ryder, Susan P Irwin, Wyn Burbridge, Hardeep Gandhi, Tahira Bashir, Rachael A Allden, Mordel Wilson, Melanie Wyres, Melissa Cull, Mahi Yadagiri, John P Bleasdale, Edward N Fogden, Mark R Anderson, Piya Sen Gupta


Aims: EndoBarrier is a 60 cm proximal intestinal liner, endoscopically implanted for up to 1 year, designed to mimic the bypass aspect of Roux-en-Y gastric bypass surgery. We aimed to assess its safety and efficacy in patients with advanced diabesity.

Methods: Since October 2014 we have implanted 62 Endo-Barriers in our NHS service. By November 2018 all were explanted. Outcomes were monitored in a registry.

Results: In 61 of the 62 patients (98.4%) (age 51.4±7.2 years, 54.1% male, 57.4% Europid, diabetes duration 12.0 (8.0–19.5) years, 57.4% insulin-treated, BMI 41.9±7.4 kg/m2) with implant and explant data, mean±SD HbA1c fell by 23.7±21.4 mmol/mol from 80.2±22.5 to 56.5±11.5 mmol/mol (p<0.001), weight fell by 15.9±8.5 kg from 122.6±27.9 to 106.7±28.9 kg (p<0.001), systolic blood pressure from 138.5±15.0 to 125.8±14.6 mmHg (p<0.001), cholesterol from 4.7±1.4 to 3.9±0.9 mmol/L (p<0.001) and alanine aminotransferase (a marker for non-alcoholic fatty liver disease) from 33.2±19.8 to 19.5±11.4 U/L (p<0.001). In the 35 insulin-treated patients, median (IQR) insulin dose reduced from 100 (54–140) to 40 (0–70) units (p<0.001), with 10/35 (28.6%) discontinuing insulin. There were significant falls (UKPDS Risk Engine v2) in the risk of coronary heart disease (CHD) and stroke, suggesting that EndoBarrier treatment in 100 such patients could prevent 8 events of CHD or stroke and save 6 lives over the 10 years. Ten of the 62 patients (16%) required early removal (4 for gastrointestinal haemorrhage, 2 for liver abscess, 1 for another intra-abdominal abscess and 3 for gastrointestinal symptoms). All made a full recovery following device removal and most derived benefit despite early removal.

Conclusion: EndoBarrier was highly effective in this setting in patients with advanced diabetes and obesity. Given the high cardiovascular and microvascular risk of these patients, benefits might outweigh risks. As an endoscopic procedure it is relatively simple and non-invasive. Early removal rates require monitoring and there needs to be increased focus on preventing complications but, on balance, EndoBarrier deserves further investigation as a potential treatment for wider use.


EndoBarrier, duodenal–jejunal bypass liner, DJBL, obesity, type 2 diabetes, diabesity, bariatric surgery

Full Text:



The EndoBarrier Gastrointestinal Liner with Delivery System: instructions for use. GID part number 50-10-00552 Rev N. (accessed 10 September 2019)

de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal–jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg 2013;23:1354–60.

Betzel B, Homan J, Aarts EO, et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc 2017;31:2881–91.

Kaválková P, Mráz M, Trachta P, et al. Endocrine effects of duodenal–jejunal exclusion in obese patients with type 2 diabetes mellitus. J Endocrinol 2016; 231:11–22.

Koehestanie P, Dogan K, Berends F, et al. Duodenal-jejunal bypass liner implantation provokes rapid weight loss and improved glycemic control, accompanied by elevated fasting ghrelin levels. Endosc Int Open 2014; 2(1):E21–E27.

Jirapinyo, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care 2018;41(5):1106–15.

Sen Gupta P, Drummond RS, McGowan BM, et al. One year efficacy, safety and tolerability of duodenal exclusion using Endobarrier as an adjunct to glucagonlike-peptide-1 (GLP-1) therapy: a randomised controlled trial. Diabetologia 2016;59(Suppl 1):S272, 569.

Ryder REJ. One year efficacy, safety and tolerability of duodenal exclusion using Endobarrier as an adjunct to glucagon-like-peptide-1 (GLP-1) therapy: a randomised controlled trial. ePoster video presentation, European Association for the Study of Diabetes, Munich, 2016.!resources/one-year-efficacy-safety-and-tolerability-of-duodenal-exclusion-using-endobarrier-as-an-adjunct-to-glucagon-like-peptide-1-glp-1-therapy-a-randomised-controlled-trial-fe99ad0e-0918-4199-9aa7-a423f5555b65 (accessed 10 September 2019)

Hayee B, Sen Gupta P, Anderson M, et al. Endoscopic proximal intestinal exclusion can improve non-alcoholic fatty liver disease (NAFLD) in patients with diabesity. Proceedings of the Digestive Diseases Week (DDW), San Diego, May 2016.

International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017.

Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54(10):2506–14.

Davies MJ. Management of hyperglycaemia in type 2 diabetes: the 2018 consensus report by ADA/EASD Insights from one of the authors. Br J Diabetes 2018;18:137–40.

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61(12):2461–98.

Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080–6.

National Institute for Health and Care Excellence (NICE). Insulin therapy in type 2 diabetes. Last revised July 2016.!scenario (accessed 9 September 2019).

Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143(8):559–69.

Pories WJ, Caro JF, Flickinger EG, et al. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 1987;206:316–23.

Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006; 244:741–9.

Kashyap SR, Daud S, Kelly KR, et al. Acute effects of gastric bypass vs gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond) 2010; 34:462–71.

The ABCD EndoBarrier Worldwide Registry. (accessed 8 November 2019).

The UKPDS Risk Engine v2.0. (accessed 10 September 2019).

NHS England. Friends and Family Test. (accessed 10 September 2019).

GI Dynamics. GI Dynamics receives CE Certificate of Conformity withdrawal notice for EndoBarrier. (accessed 11 September 2019).

Birmingham EndoBarrier Treated Patients. Pictures obtained with written consent for online publication. (accessed 1 November 2019).

Interviews with Birmingham EndoBarrier Treated patients. Video footage obtained with written consent for online publication. y4pwwokc (accessed 1 November 2019).

United Kingdom Prospective Diabetes Study (UKPDS). Main Trial. (accessed 10 September 2019).

UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703–13.

UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713–20.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131):837–53.

GI Dynamics. A randomized, multi-center, pivotal efficacy and safety study evaluating the EndoBarrier® system for glycemic improvement in patients with inadequately controlled type 2 diabetes and obesity (FDA IDE STEP-1 study). (accessed 10 September 2019).

Drummond RS, Timmons J, Talla M, Sen Gupta P, Ryder REJ. Liver abscess secondary to a duodenal-jejunal bypass liner (DJBL) successfully treated with antibiotics but without removal of the device. Proceedings of the ABCD Spring Meeting, 2018. (accessed 27 November 2019).

GI Dynamics Announces Selection of New Notified Body. (accessed 5 November 2019).



  • There are currently no refbacks.

The Journal of the Association of British Clinical Diabetologists